Larsimont D - Search Results

1

Eighteen months clinical experience with the GeneSearch breast lymph node assay.

Veys I, Durbecq V, Majjaj S, Schobbens JC, Noterman D, Sirtaine N, Martinez MD, Hertens D, Feoli F, Bourgeois P, Nogaret JM, Larsimont D. Veys I, et al. Among authors: larsimont d. Am J Surg. 2009 Aug;198(2):203-9. doi: 10.1016/j.amjsurg.2008.09.012. Epub 2009 Feb 27. Am J Surg. 2009. PMID: 19249740

2

Leiomyosarcoma of the mesocolon.

Heymans O, Lemaitre J, Choghari C, Larsimont D, Ohana M, Drijski J, Nogaret JM. Heymans O, et al. Among authors: larsimont d. Acta Chir Belg. 1998 Dec;98(6):261-3. Acta Chir Belg. 1998. PMID: 9922814

3

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.

Di Leo A, Crown J, Nogaret JM, Duffy K, Bartholomeus S, Dolci S, Rowan S, O'Higgins N, Paesmans M, Larsimont D, Riva A, Piccart MJ. Di Leo A, et al. Among authors: larsimont d. Ann Oncol. 2000 Feb;11(2):169-75. doi: 10.1023/a:1008345432342. Ann Oncol. 2000. PMID: 10761751 Free article. Clinical Trial.

4

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.

Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, Di Leo A, Nogaret JM, Hertens D, Verhest A, Larsimont D. Gancberg D, et al. Among authors: larsimont d. Am J Clin Pathol. 2000 May;113(5):675-82. doi: 10.1309/0F58-0GRX-FK4R-A6VA. Am J Clin Pathol. 2000. PMID: 10800400

5

Trisomy 6 in Merkel cell carcinoma: a recurrent chromosomal aberration.

Gancberg D, Feoli F, Hamels J, de Saint-Aubain N, André J, Rouas G, Verhest A, Larsimont D. Gancberg D, et al. Among authors: larsimont d. Histopathology. 2000 Nov;37(5):445-51. doi: 10.1046/j.1365-2559.2000.01011.x. Histopathology. 2000. PMID: 11119126

6

In situ amplification of oestrogen receptor alpha mRNA in breast cancer cell lines and tumours.

Lespagnard L, Gancberg D, Maaroufi Y, Leclercq G, Larsimont D, Verhest A. Lespagnard L, et al. Among authors: larsimont d. Mol Pathol. 2001 Jun;54(3):197-9. doi: 10.1136/mp.54.3.197. Mol Pathol. 2001. PMID: 11376135 Free PMC article.

7

Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.

Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S, Ferreira F, Paesmans M, Piccart M. Cardoso F, et al. Among authors: larsimont d. Ann Oncol. 2001 May;12(5):615-20. doi: 10.1023/a:1011182524684. Ann Oncol. 2001. PMID: 11432618 Free article.

8

[Sentinel node involvement in T0-T1 breast cancers].

Dequanter D, Hertens D, Veys I, Nogaret JM, Larsimont D, Bourgeois P. Dequanter D, et al. Among authors: larsimont d. Ann Chir. 2001 Sep;126(7):654-8. doi: 10.1016/s0003-3944(01)00578-8. Ann Chir. 2001. PMID: 11676237 French.

9

[Sentinel node biopsy and invasive breast cancer: towards a new minimal surgical approach].

Nogaret JM, Hertens D, Veys I, Bourgeois P, Larsimont D. Nogaret JM, et al. Among authors: larsimont d. Rev Med Brux. 2002 Jun;23(3):A175-6. Rev Med Brux. 2002. PMID: 12143157 French. No abstract available.

10

Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

Di Leo A, Cardoso F, Durbecq V, Giuliani R, Mano M, Atalay G, Larsimont D, Sotiriou C, Biganzoli L, Piccart MJ. Di Leo A, et al. Among authors: larsimont d. Int J Clin Oncol. 2002 Aug;7(4):245-53. doi: 10.1007/s101470200036. Int J Clin Oncol. 2002. PMID: 12202978 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

313 results

Search Page

Filters